MT-031 is a multifunctional drug designed for the treatment of dementia and Alzheimer Disease. Its structure combines Rivastigmine (Exelon) and Rasagiline (Azilect) moieties. It works as a dual Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A

Our findings demonstrated that MT-031 has the following attributes:

  • A brain permeable novel multifunctional MAO-AChE/BuChe inhibitor
  • Possesses neuroprotective activity
  • Anti-inflammatory properties
  • Cognitive enhancing activity’s
  • Memory enhancing
  • Intellectual Property

    The molecule, its derivatives and applications are protected by the US and European recently granted patent.

    Read more


    The new generation of therapy for Parkinson .


    ResQ Medical

    Treating Postpartum Hemorrhage the physiological way

    ResQ Medical is developing ALMA, a unique and innovative solution for treating Postpartum Hemorrhage (PPH) which is a life-threatening condition.

    ALMA is attentive to the natural physiological mechanism of the uterus to deal with PPH.

    Our approach with ALMA is to support the natural contraction of the uterus which in turn leads to the cessation of the bleeding as occurring naturally in any normal birth, and which doesn’t occur in the case of PPH. This innovative approach contrasts with the medical devices used today, which are based on inserting and inflating a balloon inside the uterine cavity- causing the uterus to expend against the natural mechanism of the body.

    Read more



    BioShai Ltd. focuses on commercializing PDx™, the first blood test for diagnosing Parkinson’s disease (PD). PDx™ increases diagnostic certainty at an early stage, obviating the need to wait for disease progression. PDx™ expected to significantly improve the development of novel PD drugs, by reducing False-Positive enrolment for clinical trials. The company has been honored with an award and support from the Michael J. Fox Foundation for testing PDx™ genes in the Parkinson’s Progression Markers Initiative (PPMI) clinical study.

    BioShai’s expert management has successfully commercialized lab tests. The company is nearing completion of the PDx™ development plan and expects to receive its CE mark for the PDx™ assay in 2019, after which it will initiate beta sites (final stage testing) in Israel and Italy.

    Read more